Posted by Michael Wonder on 19 Mar 2020
Getting value right: the case for indirect benefits
19 March 2020 - According to the most recent estimates from the Centers for Medicare and Medicaid Services Office of the Actuary, health care spending is projected to reach almost 20 percent of gross domestic product by 2027.
Although national health expenditures have steadily increased for decades, there is mounting public consensus that US health spending growth has become unsustainable and unaffordable.
In response to rising health spending, new value-based assessment programs have been introduced by the American College of Cardiology in partnership with the American Heart Association, the American Society of Clinical Oncology, the Institute for Clinical and Economic Review, Memorial Sloan Kettering Cancer Center, the National Comprehensive Cancer Network, the Innovation and Value Initiative, and Avalere in partnership with FasterCures to help health care decision makers assess the value of prescription drugs, medical devices, and innovative services entering the market.
